{"name":"Sarcoma Alliance for Research through Collaboration","slug":"sarcoma-alliance-for-research-through-collaboration","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Bezuclastinib in combination with sunitinib","genericName":"Bezuclastinib in combination with sunitinib","slug":"bezuclastinib-in-combination-with-sunitinib","indication":"Gastrointestinal stromal tumors (GIST)","status":"phase_2"}]}],"pipeline":[{"name":"Bezuclastinib in combination with sunitinib","genericName":"Bezuclastinib in combination with sunitinib","slug":"bezuclastinib-in-combination-with-sunitinib","phase":"phase_2","mechanism":"Bezuclastinib is a tyrosine kinase inhibitor that targets KIT and PDGFRα, and in combination with sunitinib, it is used to treat gastrointestinal stromal tumors (GIST).","indications":["Gastrointestinal stromal tumors (GIST)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQTFF5S0N3MDEyeGg3bUQ1UGNJa3BpeDN6aDJhckpERDNyTnJvSEJSX2o5cGtQREJGUllIY2dma0ozMDJla2ZWTUNQQ0lIelZDVFRJZXVqMjNMWWVQVDZ0cE9aM1JLckRNYW0yM0NOSjJ5aVpRbXZvSS1Rd2ZsdjRxdkx1anAtaVVSSXhSaUhpRGJoNFBHWlhoLUVub195WW01UTVDT3o1eGhQakx5bTVWckwyUk9kX2tydmNBa0Utd3JNZGJiTV9OU3NwdE9zblZ2RjhGVGtOc3dWX0pYaWZRTnc0WDdCZUk?oc=5","date":"2025-08-29","type":"regulatory","source":"Business Wire India","summary":"Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma - Business Wire India","headline":"Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPc2x6Z1lEY1NoSHFtWU56RmJPVUpaVWZHVkQwNmRGcVdOZXlLM2dGemIwN08tQjh4UHpFTW94bHZfQ2ZlQ2ZjOVRNRU5GYTcwSzY1YkRkc0hJbGdQY0xhZGlfelhGSFhqY0NsbTBKYi1SaDRXQ2tyREhEbUw1Nk1vOEdkNDR4MnE1X0Y0TFR3MzJVbnRGTWJjWHZYZm1UN3BnZE5TeWM2Rk9UUlNMSHd6ZG0zYjJoWlV6aWtHQWlxc2JHZThaR0ZwalEzVUUyM1pRRDZ3R013Xy0tQ0I5Z1VJUmZlY0hkM3BaaFc0?oc=5","date":"2025-06-10","type":"deal","source":"PR Newswire","summary":"Curadev Expands Strategic Collaboration for CRD3874-SI Through MSK Therapeutics Accelerator Program - PR Newswire","headline":"Curadev Expands Strategic Collaboration for CRD3874-SI Through MSK Therapeutics Accelerator Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNZzVoZ1NlVWdzOGpSYjZ3UFpQS0lpZ0xVeG5SWW5MSHoyc09kRm5mSjI2cU9fenF2dlkxaTEtcFNsc19nU0NKUG91ZFR5U05teDhKeGQyZ0dKYlJ4SGVoWVdVa3JkNDcxX185Q092OTBHangyNzNpNmc5eVZsWHpNUE1HS3FramM0VFl4aldCTS11cm9wRW0zQmxrUV9GYm8wYnVIaUxkUUdTQUVnMERsb1RYWE9TenJ4U3pneGRSXzJDUk00eEdMR1Z4UWhkR08xZ1Z4c2w5Yw?oc=5","date":"2024-08-29","type":"pipeline","source":"PR Newswire","summary":"Tampa General Hospital Cancer Institute Joins Elite Global Registry to Fight Sarcoma - PR Newswire","headline":"Tampa General Hospital Cancer Institute Joins Elite Global Registry to Fight Sarcoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE8tdDNzSE1ESWJHbGt5N3lYWXJLNVVldmV6Vlp5Nk9KZEl4M0s3ZGJOTlpNcDc3S2R5dlRaQ2tFTENLTGRrVF9TRGlYLTFPRVFUeE5zMjRfMA?oc=5","date":"2024-06-11","type":"deal","source":"ASCO Publications","summary":"Leveraging Patient Engagement Through Collaboration for Improved Global Health Outcomes in Sarcoma - ASCO Publications","headline":"Leveraging Patient Engagement Through Collaboration for Improved Global Health Outcomes in Sarcoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBvcTZHaFBvN2JBZF9nOFYzbFlsWFFLa2I3OXJaYVlMRXlkaFNMRENyUmpqVDJOdjNod3VTbVpIcUVLTkNhSGt2RmNRWHZab1dFajdzZldhYmdPVlphWVBOaGx0di1NNTdfd25GZlY4OE45cmFPYWZiNEtn?oc=5","date":"2019-09-19","type":"pipeline","source":"acsjournals.onlinelibrary.wiley.com","summary":"Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network - acsjournals.onlinelibrary.wiley.com","headline":"Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNcFBJR1d4Wk9KcVlvZWFxRmtMMlZETnVkZXpYY3NCNXd1ZjE4UWw2djBVMWR4MWpqMm1wcXpubVBVeUt0QTVkN21zOTdxZGpxcTdNX1A0MTJ3cms4bEN2dU9lYVdLdk1veHZTaDNsYmNrcGF0Z2tTV2xZWVE0X3dxeXQzaWZpNlVQaFZqX0UzRGdRUXNJa2dodF94S1I?oc=5","date":"2019-05-23","type":"pipeline","source":"Northwestern University","summary":"Drug Shows Benefit in Metastatic Osteosarcoma - Northwestern University","headline":"Drug Shows Benefit in Metastatic Osteosarcoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPbFl3YkEzTVFwV0JZcFNqaXpnaDdteTBhN3hlZmJXdjNrcnRwM2laUFV0Qng1XzBtOUtfZnlyYUduXzV5T2I1WE9qOVpOVnBoMVUzQlVrXzBtcjNCZG13T0FLWWtGVHAwcUVsVzJPeTRPMlhVdlA5enBFeXRwZ1JwTEZXd3FBclFfbjBtVmlOcUI3OVRoTnV3WE5TbWV2cHFh?oc=5","date":"2019-04-26","type":"pipeline","source":"Oncology Nurse Advisor","summary":"Management of Recurrent Ewing Sarcoma: Challenges and Approaches - Oncology Nurse Advisor","headline":"Management of Recurrent Ewing Sarcoma: Challenges and Approaches","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFA1UG1nVWdzRERDV29WSnhJUks0RU1mVE45VFVQYk84RDJBUzFMUDR0TUw3eC1uZDVtVllGNkdzRzhnRUVXenFFRTg1bEY4NkN0SnN4NkFKWXpYaEE0RkdCUg?oc=5","date":"2018-12-19","type":"pipeline","source":"NEJM","summary":"Sorafenib for Advanced and Refractory Desmoid Tumors - NEJM","headline":"Sorafenib for Advanced and Refractory Desmoid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOWXkzZC01aks5LWRkVXBKbWF3cnJ5WVYyMkRWTzhIS2o5UUtUbnFUZkhWdUh5eEdvSno0UG9mNGxLN3FOaTBZOEt5UUhzVnpFWjU3VU12UFg2OWRqVGVGT2VZbHJqeGJ2ejlkOVRfM0NyVDJTVkJ2RTIwdlc2cGNDLUFabXZMcHBo0gGIAUFVX3lxTE5ZeTNkLTVqSzktZGRVcEptYXdycnlZVjIyRFZPOEhLajlRS1RucVRmSFZ1SHl4R29KejRQb2Y0bEs3cU5pMFk4S3lRSHNWekVaNTdVTXZQWDY5ZGpUZUZPZVlscmp4YnZ6OWQ5VF8zQ3JUMlNWQnZFMjB2VzZwY0MtQVptdkxwcGg?oc=5","date":"2017-01-24","type":"trial","source":"Newswise","summary":"Study Unveils New Way to Starve Tumors to Death | Newswise - Newswise","headline":"Study Unveils New Way to Starve Tumors to Death | Newswise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOUG9hTEt5N281T2VCeHhrT2NsVVhRYk9Ebk5aZVFINTZObHFtMG02RUhzUW9jZzZHM3dBb0w0Z3NBS0xFTThGalpLaVJKamt1ZERPN2RDcFVSZ0R6M0J3bTNKbTc5dHpHTk9MaDUwZ2F3Z3Vydm9hN2JkRk1KZGI4bTlfWTdzMzFlV1FZ?oc=5","date":"2017-01-09","type":"pipeline","source":"The Lancet","summary":"Has the time come for metronomics in low-income and middle-income countries? - The Lancet","headline":"Has the time come for metronomics in low-income and middle-income countries?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNbkRnQXBNVklSWXFNemxQdEswZFFLNTZHX0RkdDhVNVU3YmRfQ3A4bk85OUgzTXJZQkoyTkJ0aEtNNGJwUHhXNnRuaVBoVzdEeHlqRmtJUWtrY0RSNFNxNW5xUDMzSFF3dnlDY3BmWFM3WHhPRmlQRkJ1NEJJTmdjbkw2RHBzSlFTU043ZnFpLUw5Nk9WOS15dDVKMEVRNVVIc1E4S19JeFZsdm5SUDU4?oc=5","date":"2015-12-07","type":"pipeline","source":"The Pharma Letter","summary":"Set-back for Merck, as it drops further development of evofosfamide - The Pharma Letter","headline":"Set-back for Merck, as it drops further development of evofosfamide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTjg3NnRnSlE4TkR6eGVZNUVXU1FrRXVlUGI3N2VnU1M2a1NiekFMeXQtRm1JTC03Sk5jcFVxdTUtY1BpVEJDcUtVWVRuV1FLdE1hYTR2dHdvLVBiMjVvUmlibmlXb0hodFEyVUZIQl9Ub0t0c19tUGNXVjM3a0lIZFhRNG1HVHc?oc=5","date":"2011-05-16","type":"pipeline","source":"Fred Hutchinson Cancer Center","summary":"Yee Lab’s Pollack wins $300,000 sarcoma award - Fred Hutchinson Cancer Center","headline":"Yee Lab’s Pollack wins $300,000 sarcoma award","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}